Company(ies): Synta Pharmaceuticals
Principal Therapy Area: Cancer
£195 / $340 / €245
STA-909 is a synthetic, orally-bioavailable heat shock protein 90 (Hsp90) inhibitor that is structurally unrelated to first-generation Hsp inhibitors, namely geldanamycin and its derivatives. Hsp90 is a molecular chaperone that facilitates the correct folding of specific signal transduction proteins involved in cell proliferation, including human epidermal growth factor receptor-2 (HER2), vascular endothelial growth factor (VEGF), Akt and Raf kinases. Inhibiting Hsp90 prevents the refolding of key oncogenic proteins, preventing cell proliferation and survival. STA-9090 has been shown preclinically to inhibit many of these critical oncogenic proteins such as HIF1alpha, Kit, Met, HER2, EGFr, Akt, CDK4, Bcr-abl, BRAF, RAF1 and WT1.
Use this Cancer Drug Futures report to analyse key drivers and dampeners of success
An extensive review of the factors which can affect this product's clinical and commercial performance. Each drug report provides and covers…
What you get
A copy of the Cancer Drug Futures report(s) in print or pdf as you wish
Are you interested in more than one product, indication or therapy area?
Why not build a specific drug futures library and save money!
We appreciate that some customers will need to review many products. That is why, if you buy more than 5 Cancer Drug Futures reports of your choice, we can arrange
Customers focussing on specific disease areas can benefit from buying our cost-effective Cancer Drug Futures collections. Collections are available for the following cancer sectors:
For further information on the products covered, discounts, distribution or a demonstration, please click on the link for firstname.lastname@example.org